Injectable Platelet Rich Fibrin With Demineralized Freeze-dried Bone Allograft in Treatment of Intraosseous Defects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03900013 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 2, 2019
Last Update Posted : February 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Intrabony Periodontal Defect | Procedure: Injectable platelet rich fibrin combined with DFDBA Procedure: Demineralized Freeze Dried Bone Allograft | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | Due to the type of intervention, only the outcome assessor and the statistician will be blinded. |
| Primary Purpose: | Treatment |
| Official Title: | Clinical and Radiographic Evaluation of Injectable PRF With Demineralized Freeze-Dried Bone Allograft (DFDBA) Compared to (DFDBA) in Treatment of Intraosseous Defects in Patients With Stage III Periodontitis: A Randomized Clinical Trial |
| Actual Study Start Date : | September 20, 2019 |
| Estimated Primary Completion Date : | October 20, 2021 |
| Estimated Study Completion Date : | December 20, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Injectable Platelet Rich Fibrin (i-PRF) with DFDBA
In i-PRF assigned group, 10 cc of blood per intraosseous defect will be collected right after administering the anaesthesia and will be processed according to the technique proposed by Choukroun et al., 2017 (centrifuged at 700 rpm, for 2-3 minutes). The yellow part will be collected using a syringe and added to a cup that contains the bone grafting material. The i-PRF consolidated bone graft will placed into the intraosseous defect. |
Procedure: Injectable platelet rich fibrin combined with DFDBA
The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect |
|
Active Comparator: Demineralized Freeze-Dried Bone Allograft (DFDBA) alone
After debridement and intraoperative recordings, in the control group, the bone graft material will be placed in the intraosseous defect without overfilling.
|
Procedure: Demineralized Freeze Dried Bone Allograft
Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect |
- Clinical attachment level gain (CAL) [ Time Frame: CAL will be measured at base line, 3, 6, and 9 months postoperative ]CAL will be measured from the cemento-enamel junction to the bottom of the gingival sulcus/periodontal pocket using the University of North Carolina periodontal probe at six sites per tooth.
- Probing Depth (PD) [ Time Frame: PD will be measured at base line, 3, 6, and 9 months postoperative ]PD will be measured from the gingival margin to the bottom of the gingival sulcus/ periodontal pocket using the University of North Carolina periodontal probe at six sites per tooth.
- Radiographic defect fill (IBD) [ Time Frame: Radiographic defect fill will be measured at base line, 6, and 9 months postoperative ]The depth of intrabony defect will be measured from the alveolar bone crest to the base of the defect at baseline, six months and after nine months to detect the amount of bone fill Individually customized bite blocks and parallel-angle technique will be used to obtain standardized radiograph. Radiographs will be scanned and the radiographic defect fill depth will be measured by a computer-aided software program
- Gingival Recession Depth (RD) [ Time Frame: RD will be measured at base line, 3, 6, and 9 months postoperative ]RD will be measured from the cemento-enamel junction to the most apical extension of the gingival margin using the University of North Carolina periodontal probe at six sites per tooth.
- Post-surgical patient satisfaction [ Time Frame: After 9 months postoperative ]
A 3-item questionnaire will be asked to the patients and shall use a 7-points answer scale. These items will be:
Would you experience the same surgery another time? Would you advice others with the surgery? To what extent are you satisfied with the results? 7 points mean the best
1 means the worst
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Type III periodontitis patient having at least one tooth with 2-wall, 3-wall, or combined 2- to 3-wall intraosseous defect ≥ 3 mm in depth (assessed by bone sounding, radiographic examination) with clinical attachment level ≥ 5 mm and pocket depth ≥ 6 mm.
- Defect not extending to a root furcation area
- Vital teeth
- Non-smokers.
- No history of intake of antibiotics or other medications affecting the periodontium in the previous 6 months.
- No periodontal therapy carried out in the past 6 months.
- Able to sign an informed consent form.
- Patients age between 25 and 50 years old.
- Patients who are cooperative, motivated, and hygiene conscious.
- Systemically free according to Cornell Medical Index
Exclusion Criteria:
- Pregnancy or breast feeding
- The presence of an orthodontic appliance
- Teeth mobility greater than grade I
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03900013
| Egypt | |
| Faculty of Dentistry Cairo University | |
| Cairo, Egypt, 12613 | |
| Study Director: | Manal Hosny, Professor | Cairo University |
| Responsible Party: | Mashaal Mohammed Abdullah Mohammed, Principal Investigator, Cairo University |
| ClinicalTrials.gov Identifier: | NCT03900013 |
| Other Study ID Numbers: |
MASH2019 |
| First Posted: | April 2, 2019 Key Record Dates |
| Last Update Posted: | February 4, 2021 |
| Last Verified: | February 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Injectable platelet rich fibrin I-PRF Demineralized Freeze-Dried Bone Allograft DFDBA |
Stage 3 periodontitis 3 wall intraosseous defect 2 wall intraosseous defect |
|
Periodontitis Periodontal Diseases Mouth Diseases Stomatognathic Diseases |

